SG Americas Securities LLC Purchases 5,197 Shares of Guardant Health, Inc. $GH

SG Americas Securities LLC raised its position in Guardant Health, Inc. (NASDAQ:GH) by 30.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,244 shares of the company’s stock after buying an additional 5,197 shares during the period. SG Americas Securities LLC’s holdings in Guardant Health were worth $2,055,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of GH. Alyeska Investment Group L.P. bought a new position in shares of Guardant Health in the third quarter valued at approximately $114,421,000. Price T Rowe Associates Inc. MD boosted its position in Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after purchasing an additional 1,414,441 shares during the last quarter. Norges Bank bought a new position in Guardant Health in the 4th quarter valued at $128,499,000. Summit Partners Public Asset Management LLC grew its stake in Guardant Health by 674.5% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock valued at $87,019,000 after purchasing an additional 741,958 shares during the period. Finally, Franklin Resources Inc. increased its position in shares of Guardant Health by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after purchasing an additional 606,368 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Up 13.8%

NASDAQ GH opened at $170.77 on Thursday. The company has a market cap of $22.64 billion, a PE ratio of -50.37 and a beta of 1.59. Guardant Health, Inc. has a 52 week low of $40.35 and a 52 week high of $172.61. The firm’s 50-day simple moving average is $116.77 and its two-hundred day simple moving average is $105.20.

Insider Activity at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 1,951 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $131.16, for a total transaction of $255,893.16. Following the sale, the director owned 11,048 shares of the company’s stock, valued at $1,449,055.68. The trade was a 15.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the sale, the chief executive officer owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 712,513 shares of company stock worth $90,921,587 in the last ninety days. Insiders own 5.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. lifted their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. UBS Group set a $150.00 price objective on shares of Guardant Health in a report on Wednesday, June 24th. Royal Bank Of Canada assumed coverage on shares of Guardant Health in a research report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 price objective on the stock. BTIG Research boosted their target price on shares of Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Mizuho increased their target price on shares of Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $146.18.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.